Cleveland BioLabs [CBLI] has completed the technology transfer to its manufacturing partner for Protectan CBLB502, which the company has developed for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome. Production of the first Good Manufacturing Practices compliant batch of Protectan was also completed ahead of schedule. Cleveland BioLabs submitted Protectan in response to a Defense Department Request for Proposals. A contract would provide funding for development of the countermeasure through approval by the Food and Drug Administration,…
Cleveland BioLabs Completes Manufacturing Process for Radiation Drug
SHARE:
